The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 65.00
Bid: 64.00
Ask: 66.00
Change: 0.00 (0.00%)
Spread: 2.00 (3.125%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 65.00
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Progress Report on Trials and Cost Reduction

17 Aug 2015 07:00

RNS Number : 1851W
MyCelx Technologies Corporation
17 August 2015
 

MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)

 

Progress Report on Trials and Cost Reduction Initiatives

 

MYCELX Technologies Corporation (AIM: MYX), the clean water technology company providing patented solutions for commercial industrial markets worldwide, announces a progress report on trials in its key geographies and an update on cost cutting measures that are currently being implemented.

MYCELX is pleased to report progress in its three key geographies with regards to new installations and trials. The Company has recently completed its first installation for full water recycle and reuse for hydraulic fracturing in West Texas on a lease to purchase basis. Post successful trials, the system was installed to reduce operational costs through the production of high quality recycled water necessary for the fracturing process. In Saudi Arabia, MYCELX has commenced a trial with a SABIC affiliate to treat wastewater from a petrochemical maintenance operation which it believes will further bolster its prior successes in the turnaround market and accelerate project awards. As previously reported, the Company continues to progress applications of its technology in the Enhanced Oil Recovery segment of the market with a successfully completed third trial at a major producer's site in India.

The Company also reports that it has updated its cost reduction initiative and implemented additional expense control measures which include its Board of Directors and Key Management participating in a reduction in cash compensation until further notice. The impact of these efforts will be a reduction of the Company's cost base to below $9m for FY2016. These measures will enable the Company to be cash neutral from operations in H2 2015 and supports MYCELX's target to be operationally cash generative in 2016. The Company will continue to actively monitor costs in order to respond to changing market conditions. All cost reduction initiatives have been carefully targeted to preserve the Company's cash position whilst not impinging on MYCELX's ability to successfully convert its existing pipeline.

 

For further information please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO Tel: +1 888 306 6843

Mark Clark, CFO

 

RFC Ambrian Limited  Tel: +44 20 3440 6800

Corporate Finance

Samantha Harrison

Alexander Millar

 

Corporate Broking

Jonathan Williams

Kim Eckhof

 

Numis Securities Limited  Tel: +44 20 7260 1000

Corporate Broking

James Black

Ben Stoop

 

Bell Pottinger  Tel: +44 20 3772 2500

Nick Lambert

Henry Lerwill

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCPKADNDBKBFFD
Date   Source Headline
15th Mar 20197:00 amRNSHolding(s) in Company
13th Mar 20197:00 amRNSIssue of Equity
28th Feb 20194:54 pmRNSResults of Fundraising
28th Feb 20197:00 amRNSProposed $1.8 million Placing
13th Feb 201910:22 amRNSTrading Update
21st Dec 20187:00 amRNSHolding(s) in Company
11th Dec 20187:15 amRNSDirectorate Changes
7th Dec 20187:00 amRNSBlock Admission Interim Update
29th Nov 20187:00 amRNSNew Project Award and Trading Update
8th Oct 20187:00 amRNSNew Project Award and Trading Update
12th Sep 20187:00 amRNSHalf Year Results Statement
27th Jul 20187:00 amRNSContract Extension in Saudi Arabia
11th Jul 20181:16 pmRNSResult of Annual Meeting
7th Jun 20184:23 pmRNSBlock listing Interim Review
7th Jun 20183:42 pmRNSAnnual Financial Report
15th May 20187:00 amRNSFinal Results for the year ending 31 December 2017
19th Apr 20187:00 amRNSNew Purchase Order Award and Equipment Sale
13th Apr 201810:18 amRNSIssue of Equity
10th Apr 20187:00 amRNSPurchase Order Award & General Manager Appointment
28th Mar 201812:48 pmRNSHolding(s) in Company
16th Feb 20187:00 amRNSIssue of Equity
6th Feb 20187:00 amRNSExtension of Contract and New Project
17th Jan 20187:00 amRNSTrading Update
7th Dec 20179:46 amRNSBlock listing Interim Review
3rd Nov 201712:39 pmRNSIssue of Equity
26th Oct 20177:30 amRNSHolding(s) in Company
9th Oct 20177:00 amRNSIssue of Equity
27th Sep 20172:44 pmRNSApplication for Block Admission
26th Sep 20175:31 pmRNSClosure of Restricted Stock Line
21st Sep 20177:00 amRNSConsolidation of Stock Lines
13th Sep 20177:00 amRNSHalf Year Results Statement
12th Jul 201712:30 pmRNSResult of Annual Meeting
7th Jul 20177:00 amRNSHalf Year Trading Update
9th Jun 201710:00 amRNSMailing of Annual Financial Report & GM Notice
7th Jun 201710:30 amRNSBlock listing Interim Review
30th May 20171:19 pmRNSDirector/PDMR Shareholding
26th May 20177:00 amRNSContract win with new SABIC affiliate customer
11th May 20177:00 amRNSFinal Results for the year ending 31 December 2016
8th May 20177:00 amRNSContract Award & Notification of Full Year Results
30th Jan 20177:00 amRNSTrading Update
7th Dec 20162:34 pmRNSBlock listing Interim Review
4th Oct 20167:00 amRNSAppointment of Nominated Adviser & Broker
14th Sep 20167:00 amRNSHalf Year Results Statement
13th Jul 20164:21 pmRNSResult of AGM
11th Jul 20167:00 amRNSHalf Year Trading Update
30th Jun 20167:00 amRNSHolding(s) in Company
24th Jun 20167:00 amRNSMyCelx and Schlumberger Sign Upstream Agreement
9th Jun 20167:00 amRNSMailing of 2015 Annual Report and Notice of AGM
7th Jun 20163:32 pmRNSBlock listing Interim Review
17th May 20167:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.